Key result
A low concentration of doxorubicin combined with resveratrol showed an additive interaction and was more effective than either drug alone in bladder cancer cell lines.
Why the study?
Doxorubicin use in bladder cancer is limited by chronic cardiotoxicity, while resveratrol has low bioavailability, prompting investigation of whether their combination could potentiate antitumor effects at lower doses.
Does the combination of doxorubicin and resveratrol improve antitumor effects in bladder cancer cells compared to either drug alone?
Does the combination of doxorubicin and resveratrol improve antitumor effects in bladder cancer cells compared to either drug alone?
Combining low-dose doxorubicin with resveratrol exerts additive antitumor effects on bladder cancer cells in vitro, which may offer a strategy to reduce doxorubicin-associated cardiotoxicity by allowing lower effective doses.
May enable lower doxorubicin doses to limit cardiotoxicity in bladder cancer; leaves open translation beyond cell lines.
The treatment of bladder cancer remains a challenge in clinical practice. Different chemotherapeutic protocols can be used; however, it is common to observe tumor recurrence and secondary effects that result in toxicity. Doxorubicin (DOX), one of the most effective anticancer agents used to treat bladder cancer, can cause chronic cardiotoxicity, limiting its use in clinical practice. Resveratrol (RES), a natural product with potential antitumor activity against bladder cancer, is associated with rapid metabolism and low bioavailability and needs to be combined with chemotherapeutic drugs to improve its use. Our study aimed to assess the therapeutic effect of a low concentration of DOX (2 µM) in combination with RES (150, 200 and 250 µM) on two bladder cancer cell lines. We investigated the mechanism of interaction between the drugs by performing cytotoxicity, clonogenic, oxidative stress, cell migration, cell morphology and nuclear division index (NDI) assays. Cytotoxicity evaluation revealed an additive interaction between RES and DOX for both cell lines. Additionally, the results of cell colony formation, oxidative stress, cell migration, cell morphology and NDI assays showed that a combination of DOX and RES was more effective than RES or DOX alone. In conclusion, a low concentration of DOX combined with RES could potentiate the antitumor effects of the drugs on bladder cancer cells, thus overcoming the secondary effects caused by DOX and the low bioavailability of resveratrol.
No takes yet. Share an insight, caveat, or question.
A 2021 study studied Bladder cancer. Doxorubicin combined with Resveratrol vs. Resveratrol or Doxorubicin alone was evaluated on Cytotoxicity, clonogenic, oxidative stress, cell migration, cell morphology and nuclear division index (NDI). A low concentration of doxorubicin combined with resveratrol showed an additive interaction and was more effective than either drug alone in bladder cancer cell lines.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: